Literature DB >> 23620561

Pulmonary impairment, not muscle injury, is associated with elevated ESR in the idiopathic inflammatory myopathies.

Jin Kyun Park, Allan C Gelber, Michael George, Sonye K Danoff, Marzouq A Qubti, Lisa Christopher-Stine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23620561      PMCID： PMC3685332          DOI： 10.1093/rheumatology/ket162

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  10 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Polymyositis and dermatomyositis (second of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-20       Impact factor: 91.245

Review 3.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

4.  Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis.

Authors:  E H Kang; E B Lee; K C Shin; C H Im; D H Chung; S K Han; Y W Song
Journal:  Rheumatology (Oxford)       Date:  2005-06-21       Impact factor: 7.580

5.  Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis.

Authors:  Paolo Amerio; Carlo Renè Girardelli; Gianluca Proietto; Pietro Forleo; Luca Cerritelli; Claudio Feliciani; Laura Colonna; Patrizia Teofoli; Pierluigi Amerio; Pietro Puddu; Damiano Abeni
Journal:  Eur J Dermatol       Date:  2002 Mar-Apr       Impact factor: 3.328

6.  Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?

Authors:  Helena Enocsson; Christopher Sjöwall; Thomas Skogh; Maija-Leena Eloranta; Lars Rönnblom; Jonas Wetterö
Journal:  Arthritis Rheum       Date:  2009-12

7.  Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis.

Authors:  Stuart M Levine; Nina Raben; Dan Xie; Frederic B Askin; Rubin Tuder; Marissa Mullins; Antony Rosen; Livia A Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2007-08

8.  Pulmonary involvement in polymyositis and in dermatomyositis.

Authors:  I Marie; P Y Hatron; E Hachulla; B Wallaert; U Michon-Pasturel; B Devulder
Journal:  J Rheumatol       Date:  1998-07       Impact factor: 4.666

Review 9.  Type 1 interferons and myositis.

Authors:  Steven A Greenberg
Journal:  Arthritis Res Ther       Date:  2010-04-14       Impact factor: 5.156

10.  The investigation of inflammatory myopathy.

Authors:  R H Edwards; D A Isenberg; C M Wiles; A Young; M L Snaith
Journal:  J R Coll Physicians Lond       Date:  1981-01
  10 in total
  3 in total

1.  Brief report: antisynthetase syndrome-associated myocarditis.

Authors:  Kavita Sharma; Ana-Maria Orbai; Dipan Desai; Oscar H Cingolani; Marc K Halushka; Lisa Christopher-Stine; Andrew L Mammen; Katherine C Wu; Sammy Zakaria
Journal:  J Card Fail       Date:  2014-07-29       Impact factor: 5.712

2.  The roles of neutrophil serine proteinases in idiopathic inflammatory myopathies.

Authors:  Siming Gao; Xiaoxia Zuo; Di Liu; Yizhi Xiao; Honglin Zhu; Huali Zhang; Hui Luo
Journal:  Arthritis Res Ther       Date:  2018-07-05       Impact factor: 5.156

3.  Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study.

Authors:  Dong Jin Go; Eun Young Lee; Eun Bong Lee; Yeong Wook Song; Maximilian Ferdinand Konig; Jin Kyun Park
Journal:  J Korean Med Sci       Date:  2016-02-04       Impact factor: 2.153
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.